Certolizumab pegol is a safe alternative tumor necrosis factor-a inhibitor (TNFi) which may offer a few benefits to psoriatic arthritis
As officials continue to investigate the death of Prince Rogers Nelson at the age of 57, talk of a prescription drug addiction has been in the forefront.
Yutao Liu, MD, PhD, Georgia Regents University, discussed how he and his team can potentially target genes to either reduce glaucoma or provide neuroprotection specifically for the mitochondria in the retina.
Looking to become the latest addition to the field of treatment options for multiple sclerosis Zinbryta continues to show positive results during clinical trials as it awaits the final steps of the regulatory approval process in the United States and elsewhere.
A patch that uses patients’ own stem cells to protect them from vision loss will soon begin phase 1 trials.
Results from the ATLAS study show that patients with wet AMD treated with Eylea experienced visual and anatomic improvements after 1 year that were sustained after 2 years.
Phase 2a trial of novel topical anti-angiogenic agent regorafenib shows lack of efficacy in neovascular age-related macular degeneration.
According to Henry Kaplan, MD, University of Louisville School of Medicine, ""One has to recognize that there are multiple approaches like gene therapy, neuro protection, stem cell transplantation, and pharmacologic manipulation of other genes really holds the greatest benefit in terms of trying to reverse the inevitable loss of vision,"
Henry Kaplan, MD, KY Lions Eye Center, University of Louisville School of Medicine, is focusing his efforts on figuring out how to preserve or recover lost central vision in patients with retinitis pigmentosa.